Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
GMAB | Copenhagen | DKK | Real-time | |
GMABc | BATS Europe | DKK | Delayed | |
GMAB | NASDAQ | USD | Real-time | |
0MGB | London | DKK | Real-time | |
GMAB | Vienna | EUR | Real-time |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Buy | Buy | Sell | Strong Sell | Strong Sell |
Technical Indicators | Strong Buy | Strong Buy | Strong Sell | Strong Sell | Strong Sell |
Summary | Strong Buy | Strong Buy | Strong Sell | Strong Sell | Strong Sell |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Emerging Patterns | |||||
Bullish Engulfing | 5H | Current | |||
Completed Patterns | |||||
Bullish Engulfing | 1M | 1 | Mar 24 | ||
Morning Doji Star | 1M | 1 | Mar 24 | ||
Morning Star | 1M | 1 | Mar 24 |
Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
---|---|---|---|---|---|---|---|---|---|
Copenhagen | 1,966.5 | 0.0 | 0.0 | 24,912 | +2.66% | DKK | |||
BATS Europe | 1,997.25 | 0.00 | 0.00 | 0 | 0.00% | DKK | |||
NASDAQ | 27.46 | 27.35 | 29.41 | 436,363 | -3.55% | USD | |||
London | 1,960.00 | 1,925.00 | 2,005.00 | 611 | +1.62% | DKK | |||
Vienna | 266.00 | 262.80 | 266.00 | 0 | +0.00% | EUR |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
Barclays | 201.95 | 202.90 | 199.08 | -2.05 | -1.00% | 15.14M | 09:59:49 | ||
AstraZeneca | 11,998.0 | 12,144.0 | 11,960.0 | -28.0 | -0.23% | 268.31K | |||
Legal & General | 235.50 | 236.40 | 234.40 | +2.70 | +1.16% | 2.21M | 09:59:51 | ||
Anglo American | 2,543.5 | 2,569.3 | 2,518.5 | -16.5 | -0.65% | 1.11M | |||
Rolls-Royce Holdings | 412.20 | 414.90 | 409.20 | +6.50 | +1.60% | 3.62M | |||
Lloyds Banking | 51.98 | 52.00 | 51.08 | +0.78 | +1.52% | 26.02M | 09:59:34 | ||
IAG | 178.30 | 179.00 | 176.80 | +2.15 | +1.22% | 2.56M | |||
HSBC | 661.60 | 665.50 | 661.10 | -0.30 | -0.05% | 2.32M | 09:59:37 | ||
J Sainsbury | 259.80 | 261.39 | 258.00 | +2.80 | +1.09% | 811.84K | |||
BAE Systems | 1,313.00 | 1,330.00 | 1,307.00 | -7.00 | -0.53% | 1.32M |
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review